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The Expression of MGMT and Ku80 in Primary Central Nervous 
System Lymphoma and Prognostic Significance 
1. Introduction 
1.1 Epidemiology, pathological classification, prognostic immunophenotype and 
prognostic factors in primary central nervous system lymphoma (PCNSL) 
1.11 Epidemiology of PCNSL 
Primary central nervous system lymphoma (PCNSL），one of the uncommon 
extra nodal lymphomas, is defined as a lymphoma involving the brain, leptomeninges, 
eyes, or spinal cord without evidence of systemic disease. PCNSL usually is a diffuse 
large B-cell lymphoma (DLBCL) with a tropism for the CNS microenvironment. 
They are lacking lymphoid structures or aggregates. The incidence of PCNSL, in 
contrast, is now increasing although it was a rare diagnostic entity during the last 3 
decades [1-4]. It has been reported in both immune compromised and immune 
competent patients, and it accounts for 1 to 3 per cent of all primary brain tumors 
[3-5]. The reported incidence is highest among patients with the acquired 
immunodeficiency syndrome(AIDS), (1.9 to 6%). PCNSL continues to be a 
prominent AIDS-defining illness [6]. 
Much attention has been given to the reported increase in incidence over the 
past 30 years, and there has been significant speculation as to the cause[7]. Some 
studies have shown stable or decreasing incidence rates and suggest that at least part 
of the reported increase may have been related to the acquired immunodeficiency 
syndrome epidemic [8]. The increasing incidence is not solely a result of its 
association with human immunodeficiency virus infection or other causes of acquired 
immunosuppressant condition such as transplantation. It also is not explained by 
improvement in diagnostic techniques.   
1.12 Pathological classification of PCNSL 
The diagnosis can be difficult, and repeated biopsies may be required once 
there is clinical suspicion of lymphoma. Brain biopsy remains the gold standard for 
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the diagnosis of PCNSL despite the fact that its symptoms and signs vary based on the 
anatomical localization and the extent of the lesion [9-11]. Tissue diagnosis is usually 
best obtained by means of stereotactic biopsy. The PCNSL shows a characteristic 
angiocentric pattern, forming cuffs of tumor cells within and around cerebral blood 
vessels. The tumor infiltrates the brain parenchyma with clusters or as individual cells. 
Most of the PCNSLs show a diffuse growth pattern with poorly defined margins, 
whereas a follicular growth pattern has not observed in PCNSL[5].  
Starting from "perithelial sarcoma" named by Bailey to the descriptor and 
―reticulum-cell sarcoma–microgliomatosis‖, the nomenclature for primary central 
nervous system lymphoma has undergone considerable evolution until the tumors 
were finally defined as ―primary central nervous system lymphoma‖. According to the 
Revised European-American Lymphoma (REAL) classification and the WHO 
classification in central nervous system tumors, the vast majority of PCNSL is 
classified as B-cell lymphomas; the most common histology is the diffuse large B-cell 
lymphoma(DLBCL), the majority of which are germinal center in origin [12]. Other 
common B-cell histologies include low-grade B-cell lymphoma, marginal zone B-cell 
lymphoma, plasmocytoma and intravascular B-cell lymphoma. T-cell variants are rare 
and account for less than 4% of all PCNSL in the western world.  
1.13 Prognostic immunophenotype 
Several recent studies have put emphasis on the analysis of protein 
expression of selected markers by IHC methods in patients with DLBCL, in order to 
define immunophenotypic profiles that better identify risk groups and prognostic 
assessments. It is met with general acceptance that Bcl-2, Survivin, Cyclin D, Ki67 
and P53 are significantly prognostic biomarkers in non-CNS DLBCL [13]. Saez et al 
analyzed the expression of 52 proteins in DLBCL and generated a different model 
derived from logistic regression analysis and based on expression of eight markers 
(cyclin E, CDK1, CDK2, SKP2, EBER, MUM1, Rb-P, and BCL6) [14]. 
However, these biomarkers expressed in CNS DLBCL are not of the same 
prognostic significance as in non- CNS DLBCL. The tumor suppressor gene p53, cell 
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cycle regulatory molecules Ki67 and antiapoptotic protein bcl-2 in PCNSL are 
expressed in a similar fashion as in extracerebral B-cell lymphomas. However, they 
seem not to have prognostic implications [15]. Lin CH concluded the same for BCL-2 
in PCNSL [16]. Although, Chang CC et al. assume a prognostic value for p53 
expressions in immune competent patients with primary CNS DLBCL [17], there is 
no recent literature regarding this issue. Survivin expression has been associated with 
a significantly shorter 5-year survival in patients with DLBCL [18], but not in PCNSL 
[19]. 
Recently, several studies were focused on the identification of clinically 
relevant prognostic markers for PCNSL. Kunishio found p27 is a predictor of 
prognosis in patients with PCNSL [20]. D'Haene repoted that endothelial hyperplasia 
and/or endothelial galectin-3 expression was shown to be an independent prognostic 
factor for PCNSL patients treated with methotrexate-based chemotherapy [21]. These 
immunophenotypes in PCNSL on the other hand were seldom studied due to its low 
incidence. There is still uncertainty with regard to many proteins expressions in 
PCNSL. 
1.14 Prognostic factors in PCNSL 
Prognostic factors are important not only for discrimination of patients with 
PCNSL into specific risk groups and for the identification and assessment of 
appropriate therapies and predict survival, but also for comparing results of clinical 
trials. Since traditional prognostic markers in non-CNS DLBCL, such as staging and 
International Prognostic Index scores are not applicable to primary CNS DLBCL. 
Several studies were initiated to search for new markers predicting survival and 
selecting an adequate therapy. 
Prognostic pathobiological biomarkers in PCNLSL have been described.   
Clinically, the International Extranodal Lymphoma Study Group (IELSG) has 
designed a score for PCNSL. This score was derived from a retrospective analysis of 
378 patients from 48 centers [22]. Age older than 60 years, Eastern Cooperative 
Oncology Group performance status higher than 1 (KPS < 70), elevated serum LDH 
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level, high CSF protein concentration, and involvement of deep regions of the brain 
(periventricular regions, basal ganglia, brainstem, and/or cerebellum) are correlated 
with an negative prognosis. These 5 parameters comprise the elements of the IELSG 
prognostic score. Another score based purely on age and KPS, was developed at the 
Memorial Sloan-Kettering Cancer Center and externally validated by using data from 
prospective trials from the Radiation Therapy Oncology Group [23]. This model score 
is simple to use and depends on data that are collected in virtually all patients. 
1.2 O6-Methylguanine DNA methyltransferase (MGMT)  
1.21 MGMT protein molecular structure and function 
In humans the MGMT gene is localized on chromosome 10q26 and 
contains five exons and four introns (length > 170 kb). The promoter region is 
CpG-rich, lacks TATA and CAAT boxes and has ten Sp1 transcription factor binding 
sites and two glucocorticoid response elements (GREs). MGMT protein, as a  DNA 
repair protein, is a small enzyme-like substance of 207 amino acids (MW of 23 kDa). 
Most of our knowledge about MGMT is based on observations after exposure to 
alkylating agents [24-26]. In several ways, MGMT protects the cellular genome from 
the mutagenic effects of alkylating agents [25].  
The MGMT-mediated repair process is unique and differs from other DNA 
repair pathways because MGMT is not part of a repair complex but acts alone. It 
restore the nucleotide to its native form by specifically removing the methyl group 
from the O6 position of guanine without causing any DNA strand breaks [25, 26]. 
This repair mechanism mediated by MGMT involves the transfer of the alkyl group 
from the alkylation site of the DNA to an internal active site represented by a cysteine 
(Cys) residue in the amino acidic sequence of the MGMT protein. After its interaction 
with O6-meG, the alkylated form of MGMT is no more available for DNA repair. For 
this reason this acceptor molecule cannot be considered an actual enzyme, and it is a 
so-called suicide enzyme. Because one molecule of MGMT removes one alkyl 
molecule, an excess of DNA adducts at the O6-position could completely deplete 
MGMT [27], therefore, it is an ideal target.  
9 
 
MGMT is ubiquitously expressed in normal human tissues, although at 
variable extent in selected tissues and on individual bases[28], but is overexpressed in 
all types of human tumors, including colon cancer, glioma, lung cancer, breast cancer, 
leukemia, lymphomas, and myeloma. The level of MGMT expression is protean in 
various tumor tissues because of epigenetic inactivation of the MGMT gene. In 
particular, hypermethylated CpG islands in the MGMT promoter seem to be the most 
important mechanism for MGMT gene silencing and for the down-regulation of the 
expression. Several studies have reported transcriptional silencing of this gene in up 
to 50% [29]. MGMT silencing is also often observed in tumors in which a number of 
other genes are suppressed by methylation. The silenced gene lists are not consistent 
in between tumors or tumor types[30]. Thus, the epigenetic alteration of MGMT 
behaves like a carcinogenic marker [27]. 
1.22 MGMT and chemosensitivity 
How to predict and surmount the cell resistance in tumor chemotherapy is a 
complex problem. The mechanism of MTMG is to remove alkyl groups created by 
alkylating chemotherapy and therefore induces chemoresistances. It has been 
observed that MGMT gene expression seems to be related to the methylation of the 
MGMT promoter, MGMT enzyme activity, protein expression and cell resistance to 
anti-tumor alkylating agents by a series of recently experiments, which could predict a 
possible chemosensitivity. Therefore the study of MGMT status could be of 
therapeutic and prognostic interest.  
Epigenetic silencing of MGMT expression by promoter methylation is a 
common event in human neoplasia. Methylation of the MGMT promoter region can 
also increase mutations in cancer[31]. It has been found that those tumors with high 
MGMT activity and abundance of MGMT protein were resistant to alkylating 
chemotherapeutics, while those with low MGMT activity and little MGMT protein 
expression were sensitive. Hence, MGMT behaves as a predictor of response to 
chemotherapy and also may be a prognostic biomarker. Given MGMT is one of the 
most important factors determining drug resistance to alkylation, strategies have been 
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developed to inhibit MGMT expression in tumors with the aid of MGMT inhibitors, 
and further enhance the anti-neoplastic efficiency of alkylating agents. 
1.24 MGMT and brain tumors 
Most of studies assessing the MGMT status in brain tumors focused on 
serial patients with glioma. The level of MGMT protein in malignant glioma varies 
widely ranging from almost undetectable to very high level. Esteller et al investigated 
the relationship between MGMT promoter methylation and response to carmustine in 
47 patients with gliomas. In this study, MGMT gene promoter methylation was 
associated with a better response to chemotherapy, greater overall survival and longer 
time to progression [32]. Several studies reported similar results recently [33, 34]. The 
low MGMT protein expression was further identified as an independent favorable 
prognostic factor in terms of OS [35]. These results were consistent with the findings 
in the large phase III EORTC/NCIC trial conducted for patients with newly diagnosed 
GBM [36].  
Only few studies about the MGMT expression in other brain tumors were 
sporadic described in the recent decade. Andersson and colleagues evaluated the 
immunohistochemical expressions and distribution of MGMT in low- and high-grade 
astrocytoma, oligodendroglioma and in different subgroups of meningioma. They 
revealed a marked heterogeneity in the expression and distribution which may be of 
importance in the selection of individualized chemotherapy [37]. De Robles et al 
found that none of the meningiomas showed MGMT gene promoter methylation and 
concluded that there is no biological rational to suggest that TMZ might have 
significant anti-meningioma activity [38]. Gonzalez-Gomez et al estimated the 
methylation status of multiple genes in Schwannomas, found a MGMT methylation of 
20% with no significant correlations between the MGMT status and clinical features 
[39]. Lassaletta and co-workers confirmed the similar results [40]. Kovacs et al 
reported a TMZ treatment caused marked clinical improvement in a 46-year-old man 
with an aggressive and prolactin secreting pituitary tumor showing a low MGMT 
expression [41]. Widhalm et al suggested the MGMT expression may serve as an 
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additional prognostic factor in nonfunctioning pituitary adenomas [42]. The MGMT 
status in PCNSL and its correlation to clinical outcome is still unknown. 
1.3 Ku80 introduction 
1.31 Ku80 protein molecular structure and function 
Ku80 (Ku86 in higher eukaryotes), a DNA repair protein, is derived from 
the XRCC5 gene localized to chromosome 2q33`q35 in human cells. Ku80 forms a 
heterodimer with Ku70, called Ku, which binds to DNA ends, nicks, gaps, and 
hairpins. In vitro, Ku forms a complex called DNA-dependent protein kinase 
(DNA-PK) by associating with a 450-kDa catalytic subunit and DNA-PKCS. Ku80, 
Ku70, DNA-PKCS, Xrcc4, and DNA ligase IV are critical for the repair of DNA ends 
by nonhomologous end joining (NHEJ). The Ku plays a key role in multiple nuclear 
processes, e.g., DNA repair, chromosome maintenance, transcription regulation and 
VJ recombination [43-45]. Although both Ku proteins and DNA-PKcs bind 
independently to the DNA ends, the greater part of this function is performed by the 
Ku70/Ku86 heterodimer, rather than DNA-PKCS itself [46]. 
Mice deleted for Ku70 or Ku80 exhibit hypersensitivity to γ -radiation, 
defective V(D)J recombination, genomic instability and early aging with low-cancer 
levels [47, 48]. This similar phenotype suggests Ku70 and Ku80 function is restricted 
to the Ku heterodimer. However, there is reason to believe Ku70 or Ku80 may 
function independent of the Ku heterodimer. Each subunit enters the nucleus through 
a different nuclear localization signal [49, 50] and Ku70 levels increase in response to 
-radiation without Ku80 [51]. Li et al suggested p53-mutant fibroblasts are more 
sensitive to streptonigrin and paraquat when deleted for Ku80 as compared with Ku70. 
Thus, Ku80 may function outside the Ku heterodimer to influence DNA damage 
repair [52]. 
1.32 Ku80 and radiosensitivity 
DNA double-strand breaks (DSB) are the major lethal lesions induced by 
ionizing radiation. Cells mutated by the deletion of any of these genes are 
hypersensitive to ionizing radiation and defective in repairing DNA double-strand 
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breaks. The capability for DNA DSB repair is crucial for inherent radiosensitivity of 
tumor and normal cells. The success of DSB repair in tumor cells is the major cause 
for radiotherapy failure, leading to prolonged tumor cell survival. Thus, molecules 
that are involved in DSB repair may be potential prognostic markers for the prediction 
of radiotherapy outcome, and hence, for optimization of treatment.  
Although there are exceptions, it is supported by results from several 
clinical studies that Ku protein expression is correlated with radiation treatment 
outcome [53-55] [56]. Upregulation of the Ku80 protein following ionizing radiation 
exposure has been reported previously [54, 57, 58]. Conversely, tumors with a low 
percentage of Ku80-positive cells tend to be radiosensitive. 
1.33 Ku80 and lymphoma  
There are some evidences that NHEJ mutations are lymphomagenic in humans. 
Artemis-deficient patients display aberrant chromosome rearrangements in peripheral 
blood lymphocytes and develop B cell lymphomas, without overt immunodeficiency 
[59]. Badle et al. described a case with a hypomorphic mutation in ligase IV, which is 
associated with acute lymphoblastic leukemia and radiosensitivity [60]. Inherited or 
acquired mutations in NHEJ factors could be important risk factors for developing 
lymphoid neoplasms. 
Despite many studies performed with established cell lines, little is known 
about Ku80 expression in lymphoma. Some studies were performed in patients with 
chronic lymphocytic leukemia (CLL) [61] and myeloma [62]. Chen TY and coworker 
stated the amount of Ku80 expression in ALL was moderately correlated with 
peripheral white blood cell counts, and high Ku80 expressers tended to respond 
poorly to therapy. They suggested that Ku80 might contribute to generally poor 
prognoses in adult ALL [63].  So far the expression and significance of Ku80 in 
primary central nervous system lymphoma or DLBCL has not been analyzed. 
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1.4 Questions and aims of the study 
As mentioned above, PCNSL， as one of the uncommon extranodal 
lymphomas, has been recently paid more attention especially for its increasing 
incidence, unsatisfactory therapy and poor prognosis. Prognostic factors are important 
not only for division of patients with PCNSL into specific risk groups for 
identification and assessment of appropriate therapies and to predict the survival, but 
also for comparing results of clinical trials. It is clear that the biological mechanism 
involved in pathogenesis of PCNSL are complex but deserve further study. Obviously, 
a better insight of its biology is crucial to improve the prognosis. If it were possible to 
interfere with the chemosensitivity and radiosensitivity of PCNSL, an alternative 
therapeutic approach might be found. 
Given MGMT is one of the most important factors determining drug 
resistance while Ku80 determining radiosensitivity, the expression of MGMT and 
Ku80 in PCNSL remains unclear. Herein, we postulate that the expression of the 
Ku80 and MGMT in PCNSL is of interest for the therapy. It is for this reason that our 
study was designed to detect the expression of MGMT and Ku80 on PCNSL by IHC 
staining to address the following questions: 1) to determine the expression level of 
Ku80 and MGMT for correlation with the clinical status of the patients. And 2) to 
evaluate the relationship between Ku80, MGMT expression level and clinical 
outcomes, thus determine whether these immunophenotypes were prognostic factors 
in PCNSL. They may be new markers for anticipating curative effects. These also 
might be strategy to the genes for future therapy in primary central nervous system 
lymphoma. 
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2. MATERIALS AND METHODS 
2.1 Patients and tissue samples 
2.11 Patient eligibility 
PCNSL tissues and clinical data were collected from 49 patients who were 
diagnosed and treated at the Department of Neurosurgery, UK S-H Campus Kiel, 
Germany. Patients were eligible for this study if they had been diagnosed with 
PCNSL. Patients selected criteria for this study: (1) Histological characteristics of 
these cases fulfilled the criteria of the World Health Organization criteria of lymphoid 
neoplasms for PCNSL, (2) Patients were required to have a life expectancy greater 
than 1 months, with detailed clinical data at diagnosis and therapy and during follow 
up, (3) Availability of adequate tissue specimens for histologic typing and 
immunohistochemistry, (4) Have adequate hematologic, renal and hepatic function. 
Patients who had a history of HIV infection or who were receiving 
immunosuppressive therapy were excluded from the study. Patients previously treated 
by radiotherapy or chemotherapy were excluded. Patients who died from recent 
complications postoperatively weren’t involved in the study. The study also excluded 
lymphomas located in spinal canal. 
In order to compare expressions of Ku80, MGMT in primary cerebral 
lymphoma and secondary cerebral lymphoma, 6 secondary cerebral lymphomas were 
involved in this study.  
2.12 Clinical data of patients 
Between May 1994 and Jan 2009, there were a total of 122 patients with a 
new histological diagnosis of PCNSL by the World Health Organization (WHO) 
criteria in the Department of Neurosurgery, UK S-H Campus Kiel, Germany. Among 
them, 49 patients were enrolled in this study. Clinical follow-up was obtained until 
July 15, 2009, or until death or lost follow-up. 20 patients had undergone craniotomy 
at the time of initial diagnosis and 29 patients had undergone stereotactic biopsy. 
Differential indication for open craniotomy was seen when the preoperative diagnosis 
of a space-occupying intracerebral lesions based on MRI scans was not suggestive of 
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primary cerebral lymphoma. Once PCNSL was diagnosed and at least two weeks had 
gone by postoperatively for physical recovery, chemotherapy or/and radiotherapy was 
started in the respective depts. of medical oncology or radiotherapy. Treatment of 
patients varied, depending on individual conditions, the stage of their disease, date of 
diagnosis, institution, and healthy conditions. All patients were followed up 
postoperatively by clinical examination and MRI scanning at three month intervals or 
when recurrence was suspected. Those patients who got a complete remission were 
followed up by phone calls and were not regularly reexamined if being in good health. 
2.13 Histological classification  
Histological characteristics of 49 PCNSLs were DLBCL. 2 cases fulfilled the 
criteria of the intravascular subtype for DLBCL. The 6 secondary cerebral lymphomas 
were classified as DLBCL.  
2.2 Immunohistochemistry 
2.21 Experimental instruments 
Medical pressure cooker：Sicomatic-L, Germany 
Electronic precision scale：A200S-*DI，SARTORIUS GMBH GOETTINGEN, Germany  
Micropipetters and tips：EPPENDORF，Germany  
Optical microscopy：OLYMPUS，BH-2，Japanese 
 
2.22 Experimental reagents 
（1）TBS （Tris-GerufferK Kodsalzlsg pH7,0） 
Tri-sodium base  (Sigma T 1503)            0.9 g 
Tris-HCL        (Sigma T 3253)            6.85g 
NaCL           (Merck 1.o64o4)           8.78g 
Distilled water                          1000 ml 
（2） EDTA-Puffer (TEC-Puffer pH7.8) 
Tri-sodium base     (Sigma T 1503)            2.5 g 
EDTA             (Merck 1.08418)           5.0 g 
Tri-Sodium Citrate   (Merck 1.06448)           3.2g 
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Distilled water                           1000 ml 
（3）AEC Reagent：Sigma  
（4）Ku80 Mouse Monoclonal Antibody:    1:200    LAB VISION    
（5）MGMT Mouse Monoclonal Antibody:  1:60     Thermo 
（6）Second antibody: Anti-Mouse and Rabbit Histofine:NICHIREI BIOSCIENCEC 
INC,  Germany 
（7）Tris                     Merck Germany 
（8）HCL                    Merck Germany 
（9）NaCL                    Merck Germany 
（10）Non-Fat Dry Milk         Roth Germany 
（11）Hematoxylin Solution       Merck Germany 
（12）3% hydrogen peroxide     Merck Germany 
 
2.23 Control samples： 
According to antibody data sheets, normal tonsil tissues obtained are served 
as normal control samples for Ku80, and colon cancer tissues are for MGMT. For 
positive and negative (omission of first antibody) control of the staining reaction, 
these sections were stained in parallel to all cases in our study cohort. Each antigen 
has a preferred method of antigen retrieval, and each antibody was optimal diluted. 
Positive control experiments are performed to find optimal staining conditions before 
immunohistochemical stains can be proceeded.  
We tried staining without antigen retrieval, and also used the heat-induced 
epitope retrieval with a pressure cooker. Antigen retrieval was tested in Tris/EDTA pH 
6.0, 7.8 and 9.0 buffers. The antigen retrieval time was controlled for 3 minutes (Ku80) 
and 10 minutes (MGMT) as soon as the cooker had reached full pressure. Antibody 
concentrations were diluted to 1:20, 1:40, 1:60, 1:80 for MGMT, and to 1:100, 1:200 
for Ku80, as recommend on the data sheets. Finally a dilution of 1:60 was determined 
as the optimal dilution for MGMT, and 1:200 for Ku80. 
 
2.24 Experimental process  
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The basic steps of the IHC protocol are as follows: fixing and embedding 
the tissue, cutting and mounting the section, deparaffinizing and rehydrating the 
section, Antigen retrieval, Immunohistochemical staining, counterstaining (if desired), 
dehydrating and stabilizing with mounting medium, viewing the staining under the 
microscope 
2.241 Deparaffinizing and rehydrating the sections 
Formalin-fixed, paraffin-embedded sections (3-µm thick) were dewaxed in 
xylene and rehydrated by passage through a graded ethanol series to distilled water. 
The step in details is performing the following washes in proper order with sections 
placed in a rack. 
1). Xylene:       2 x 5 minutes 
2). Xylene 1:1 with 100% ethanol:  2 x 5 minutes 
3). 100% ethanol:     2 x 2 minutes 
4). 96% ethanol:      2 x 2 minutes 
5). 70 % ethanol:      2 minutes 
6). Running cold distilled water to rinse 
 
2.242 Antigen retrieval 
The appropriate antigen retrieval buffer is added into the pressure cooker 
and the slides transferred from the distilled water to the pressure cooker. The pressure 
cooker is placed on the hotplate and turned on full power after securing the lid of the 
pressure cooker. The cooker has reached full pressure in 3 minutes (10minutes for 
MGMT antigen retrieval). The hotplate is turned off and placed in an empty sink. The 
pressure release valve is activated. Once de-pressurized, the slides are rinsed with 
distilled water. 
 
2.243 Immunohistochemical staining process 
1). Slides are kept in distilled water for 1 minute. 
2). Slides are kept in 70% ethanol for 1 minute. 
3). 96% ethanol for 1 minute. 
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4). Endogenous peroxidases were blocked with 3% hydrogen peroxide in 
Tris-buffered saline (TBS) for 10 minutes. 
5). 96% ethanol for 1 minute. 
6). 70% ethanol for 1 minute. 
7). Distilled water for 1 minute. 
8). Blocking of nonspecific binding was accomplished in 5% skim milk for 
10 minutes. (This step is only used for MGMT) 
9). Slides were washed in distilled water for 1 minute. (This step is only used 
for MGMT) 
10). Sections were washed 3 times in TBS for 2 minutes 
11). Drain slides for a few seconds (do not rinse) and wipe around the 
sections with tissue paper 
12). Prepare the Primary antibody diluted (1:60 for MGMT and 1:200 for 
Ku80) according to the manufacture’s protocol. 100 µL of primary 
antibody fine-tuned was added.  
13). Anti-Ku80 mouse monoclonal antibody is raised in room temperature 
for 30 minutes, and anti-MGMT is raised in room temperature overnight 
(18 hours).  
14). Slides were washed in distilled water for 2 minute after incubation. 
15). Sections were washed 3 times in TBS for 2 minutes. 
16). Incubated at room temperature for 30 minutes with 100 µL of 
anti-Mouse and rabbit histofine. (Secondary antibody） 
17). Sections were washed 3 times in distilled water for 5 minutes. 
18). Wash the slides 2 minutes in TBS for3 times. 
19). Incubated for 20 minutes at room temperature with 100 µL AEC 
complex and 1 µL 3% hydrogen peroxide, and then washed in distilled 
water for 1 minute 
20). Sections were counterstained for 5 minutes with hematoxylin. 
21). Wash slides 5 minutes and then wash in distilled water for several 
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seconds, mounted using a drop of aqua tex. 
2.25 Results evaluation 
A neuropathologist without prior knowledge of the patients’ clinical 
outcomes investigated all histologic specimens. Each tumor was evaluated for these 
gene proteins and given the percentage of positive cells. One thousand neoplastic cells 
per specimen were evaluated at x400 magnification and the ratio (%) of Ku80, 
MGMT immunoreactive neoplastic cells was counted. On the basis of the percentages 
of positive cells in the tumors, these tumors were defined as low Ku80 expression or 
low MGMT expression when there are no or fewer than 50% positive cells, and high 
expression when positive rate was equal to or more than 50%. 
 
2.3 Statistical analysis 
Complete remission (CR) was defined as the disappearance of all contrast 
enhancements in MRI in the absence of corticosteroids. Partial remission (PR) was 
defined as a 50% reduction in tumor size compared with the baseline MRI. End 
points of the study were OS and progression-free survival (PFS). PFS was evaluated 
from the first day of treatment to relapse, progression or death, or to the last date of 
follow-up, and overall survival (OS) was calculated from the first day of treatment of 
the tumor to death for any reason or to the last date of follow-up. Patients who did not 
experience the event of interest with respect to OS or PFS were considered as 
censored observations with time from first diagnosis to last follow-up visit as the 
censoring time.  
A descriptive study of all the variables included in the study was carried out. 
The quantitative variables were expressed in terms of their centralization and 
dispersion measurements, and in some cases were categorized in accordance with 
their median value. Expressions of Ku80 and MGMT between subgroups were 
analyzed by One-way ANOVA method. Chi-square test was applied to estimate the 
relation between the expression of Ku80, MGMT and patient characteristics. 
Correlation analysis was performed between the expression of Ku80 and MGMT. 
Kaplan–Meier methodology was applied in order to determine the effect of the 
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different variables on survival. Parameters possibly correlated with disease 
progression and survival were age, gender, KPS at relapse, tumor localization, 
surgical procedure, and use of alkylating agents, radiotherapy, expressions of MGMT 
and ku80 protein. These variables were estimated with their mean and 95% 
confidence interval. The end-point variable of interest was overall survival. The 
log-rank test was applied in order to verify the probabilities of accumulated survival 
in accordance with different strata of variables. A P<0.05 value was considered to be 
of statistical significance. Analyses were performed with the use of SPSS 17.0. 
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3. RESULTS 
3.1 Patient characteristics and treatment  
49 patients with PCNSL and 6 patients with secondary CNS lymphoma were 
included in this retrospective study. All data of these patients are presented in Table 1. 
  
Tab 1.  Primary clinical data of the patient characteristics 
No. Sex Age 
Locati
on 
treatme
nt 
operation Radio- 
therapy 
Alkylatin
g  agents 
Ku80 (%) MGMT (%) 
PFS 
(mon) 
OS 
(mon) 
S/D 
1 M 62 CA CT craniotomy no yes 93.8 85.6 102.0 102.0 S 
2 F 56 ML RT craniotomy yes no 46.5 44.3 5.5 7.5 D 
3 F 76 CA RT biopsy yes no 31.4 8.5 6.0 6.0 S 
4 M 57 CA RT craniotomy yes no 37.4 25.4 90.0 93.5 D 
5 F 58 SL RC biopsy yes yes 22.8 64.6 12.0 12.5 D 
6 M 79 SL NT craniotomy no no 84.4 59.4 0.0 1.0 D 
7 F 64 ML CT biopsy no yes 94.8 84.2 0.0 1.0 D 
8 F 77 SL RC biopsy yes no 7.4 5.6 4.0 4.0 D 
9 M 66 CA CT biopsy no yes 94.4 87.2 0.0 1.5 D 
10 F 80 SL RC biopsy yes no 73.4 73.0 4.0 4.0 D 
11 M 73 CA RC biopsy yes no 80.4 9.4 1.5 5.0 D 
12 M 52 OL RC biopsy yes yes 20.8 43.4 82.0 82.0 S 
13 M 73 ML CT biopsy no yes 95.8 76.2 12.0 14.0 D 
14 F 81 OL RC biopsy yes yes 59.6 78.2 2.0 2.0 S 
15 F 45 ML CT biopsy no yes 90.9 80.5 0.0 2.0 D 
16 M 56 SL CT craniotomy no yes 25.2 83.2 64.0 64.0 S 
17 F 74 ML NT craniotomy no no 63.0 71.2 0.0 1.0 D 
18 F 44 CA RC biopsy yes yes 44.0 77.6 60.0 60.0 S 
19 M 77 SL RC biopsy yes yes 78.2 73.4 30.0 30.0 S 
20 M 66 SL CT craniotomy no yes 84.2 76.4 1.0 4.0 D 
21 M 85 ML NT biopsy no no 55.8 43.8 0.0 3.0 D 
22 F 52 ML CT biopsy no yes 72.5 26.2 47.0 47.0 S 
23 M 63 ML RC biopsy yes yes 72.6 89.2 9.0 12.0 D 
24 M 44 CA RC craniotomy yes yes 48.2 62.4 27.0 27.0 S 
25 F 59 SL CT biopsy no yes 21.4 5.4 30.0 30.0 S 
26 M 68 ML CT craniotomy no yes 81.4 8.4 16.0 23.0 D 
27 F 63 SL RC biopsy yes yes 63.4 31.4 6.0 15.0 D 
28 F 46 SL RC biopsy yes yes 71.8 6.2 13.0 13.0 S 
29 M 62 SL CT biopsy no yes 83.6 11.8 9.0 11.0 D 
30 F 84 SL RC craniotomy yes no 85.6 8.4 0.0 2.5 D 
31 F 77 CA CT biopsy no yes 67.4 53.6 13.0 13.0 S 
32 F 78 SL NT biopsy no no 79.4 17.6 0.0 3.0 D 
33 M 70 SL RT biopsy yes no 68.2 90.8 11.0 11.0 S 
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34 M 67 ML RT biopsy yes no 90.6 61.4 10.0 10.0 S 
35 F 78 CA NT biopsy no no 72.4 74.8 2.0 3.0 D 
36 M 59 CA RC biopsy yes yes 44.6 45.3 72.5 72.5 S 
37 M 85 ML RT craniotomy yes no 86.2 26.5 0.0 3.0 D 
38 F 67 ML CT craniotomy no no 67.4 94.4 0.0 1.0 D 
39 M 58 CA RC craniotomy yes no 86.2 87.4 7.5 7.5 S 
40 F 42 SL CT craniotomy no yes 95.6 89.4 9.0 9.0 S 
41 M 57 SL RC biopsy yes yes 29.7 41.8 85.0 85.0 S 
42 M 47 SL CT biopsy no yes 38.1 35.8 82.0 82.0 S 
43 M 68 ML RC biopsy yes yes 75.2 48.6 89.0 89.0 S 
44 F 73 OL RT craniotomy yes no 61.8 52.5 7.0 7.0 S 
45 M 82 OL RC craniotomy yes no 65.0 11.8 145.0 145.0 S 
46 M 71 OL RC craniotomy yes no 94.2 68.3 48.0 48.0 S 
47 M 48 OL CT craniotomy no yes 70.6 23.2 40.0 40.0 S 
48 F 75 OL NT craniotomy no no 21.4 13.2 16.0 18.5 D 
49 F 6 OL CT craniotomy no yes 39.6 78.3 122.0 122.0 S 
50 M 65 OL RC craniotomy yes yes 48.5 52.2 88.0 88.0 S 
51 F 77 ML CT biopsy yes yes 64.8 93.2 2.0 11.0 D 
52 F 67 ML RC biopsy yes UNK 9.2 23.4 35.0 36.0 D 
53 F 71 SL RT biopsy yes no 67.5 33.4 2.0 4.5 D 
54 F 60 CA RC craniotomy yes UNK 77.4 79.6 40.0 49.0 D 
55 M 71 ML CT biopsy no yes 85.4 82.6 0.0 4.0 D 
Abbreviations : OS, overall survival; PFS, progress free survival; M, male; F, female; S, survival; 
D, death; SL, single lobe; CA, central area; ML, Multiple lobes; OL, other location; CT, 
chemotherapy; RT, radiotherapy; RC, radiochemotherapy; NT , no treatment; Unk, unknown. 
No.50~55 patients were diagnosed as secondary CNS lymphomas. 
 
This group comprised 26 men and 23 women, male: female ratio is 1.13, age 
varied from 6 to 85 years (mean 64.29 years). The lymphomas were located as 
follows: In 11 patients the tumor was located in central area such as cerebellar, brain 
stem thalamus, hypothalamus, para- or intra-ventricular, in 15 cases the tumor was 
restricted to a single lobe such as frontal, temporal, parietal, occipital lobe, more than 
one cerebral lobe was affected in 13 patients, in 8 patients lymphomas were located in 
the eye socket or spine.  
All patients were diagnosed as PCNSL by pathologist according to the World 
Health Organization (WHO) criteria. Biopsies were taken in 20 patients via a 
craniotomy and in 29 patients via a stereotactic biopsy. Subsequent treatment of 
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patients varied, depending on individual conditions, the stage of their disease, date of 
diagnosis, institution, and health conditions As mentioned before,these patients were 
treated in the appropriate hemato-oncological departments. Based on these factors, 17 
patients accepted HD-MTX-based, multi-agent chemotherapy and 7 patients were 
treated with sole radiotherapy. 19 patients with PCNSL underwent both chemotherapy 
and radiotherapy whereas no further therapy was applied in 6 patients (Tab. 2).  
 
Tab. 2 Treatment protocols in 49 patients 
 
36 patients were treated with polychemotherapy: CHOP +MTX protocol was 
used in 17 patients and B-ALL protocol was chosen in 11 patients. 8 patients accepted 
NOVEP or other protocol chemotherapy. A chemotherapy cycle of the CHOP+MTX 
protocol consisted of high-dose MTX, cyclophosphamide, doxorubicin, vincristine, 
and prednisone. Chemotherapy cycles were repeated every 21 days; a maximum of 6 
cycles was planned. A chemotherapy cycle of the modified B-ALL protocol consisting 
of six alternating cycles (3 x cycles A, 3 x cycle B) of polychemotherapy after a 
prephase treatment of cyclophosphamide (CP) and prednisone. During cycle A, VM26, 
ifosphamide (IFO), methotrexate (MTX), cytarabine (Ara-C), vincristine, and 
dexamethasone were given. During cycle B, Ara-C, VM26 and IFO were replaced by 
doxorubicine and cyclophosphamide. As NOVEP didn’t include any alkylating agents, 
these cases were of minor relevance concerning the MGMT status. In total 49 patients, 
28 patients were included into protocol of chemotherapy including alkylating agents, 
21 cases were treated without any alkylating agents. 25 patients underwent hyper- 
fractionated whole-brain radiotherapy (WBRT) with 40-50 Gy (2 Gy/day), which is 
considered equivalent to conventional irradiation with 20 fractions of 2 Gy, total 40 
     Treatment Radiotherapy No radiotherapy total 
Chemotherapy 19（38.8%） 17（34.7%） 36 
No chemotherapy  7（14.3%） 6（12.2%） 13 
Total 
26 23 49 
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Gy. Among them, an additional 6-10 Gy boost to gross was performed. 24 patients 
had no radiotherapy. All patients were followed up. The time of follow-up varied from 
1 month to 145 months (Mean 29.6 months). It was terminated until to death for any 
reason or to the last date of follow-up. The mean overall survival (OS) was 29.6 
months (Range 1 - 145 months), and the mean PFS was 28.4 months (Range 0 - 145 
months). 
3.2 Ku80 expression in PCNSL 
The Ku80 expression was determined by Ku80 immunohistochemistry. The 
absolute expression level of Ku80 in all groups classified according to variables were 
analyzed by One-way ANOVA method and listed in Table 3. It is found that a 
considerable variability in Ku80 expression level ranged between 7.4% and 95.8% in 
PCNSL, mean 64.1%. The results of Ku80 expression by age, gender, tumor location 
are presented in Tab. 4. 15 tumor samples (30.4%) demonstrated low Ku80 staining 
(positive rate < 50%，mean 31.9%±11.9%) (Fig. 1, 2), and 34 (69.6%) tumor samples 
demonstrated high Ku80 expression respectively (Positive rate >50%，mean 78.2%±
11.8%), (Fig. 3, 4).  
The Ku80 expression level in PCNSL (N = 49) was not correlated with the 
gender of the patients. A significant difference in Ku80 expression (weak or high) 
could be found between age<65 years group and age≥65 years group (P=0.006), 
however, no statistical relevant correlation was found between age of patient and 
Ku80 expression level (P=0.136). This revealed that the Ku80 level in age≥65 years 
patients is usually higher than in patients whose age is less than 65 years. There was 
no significant difference in Ku80 expression between primary and secondary CNS 
lymphomas (P=1.000) or between different locations of tumors (P=0.139). 
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Tab. 3 Expressions of Ku80 and MGMT analyzed by One-way ANOVA method. 
 
Variables MGMT(mean±SD) MGMT 95% CI p value 
Overall 51.3±29.5 42.8-59.8  
Sex(n)    
M (n=26) 52.9±27.8 41.7-64.1  
F (n=23) 49.5±31.9 35.7-63.3 0.692 
Age     
< 65 (n=23) 53.1±29.1 40.6-65.7  
≥ 65 (n=26) 49.7±30.4 37.4-62.0 0.689 
Tumor location    
SL (n=17) 45.5±32.4 28.8-62.2  
CA (n=11) 56.1±30.3 35.8-76.5  
ML (n=13) 58.1±27.3 41.6-74.6  
Others(n=8) 46.1±27.8 2.9-69.3 0.614 
Surgical approach    
Biopsy(n=29) 49.8±29.3 38.7-61.0  
Craniotomy(n=20) 53.5±30.6 39.2-67.8 0.676 
Treatment     
CT(n=17) 58.8±32.5 42.1-75.5  
RT(n=7) 44.2±27.3 18.9-69.5  
RC(n=19) 48.7±29.3 34.6-62.9  
No(n=6) 46.7±26.6 18.8-74.5 0.630 
Chemotherapy    
Yes(n=36) 53.5±30.8 43.1-63.9  
No(n=13) 45.3±25.9 29.7-61.0 0.399 
Alkylating agents    
Yes(n=28) 56.0±28.3 45.0-67.0  
No(n=21) 45.1±29.6 31.2-59.1 0.207 
Radiotherapy    
Yes(n=26) 47.5±28.3 36.1-59.0  
No(n=23) 55.6±31.0 42.3-69.0 0.342 
   
yes 55.2±23.5 40.2-70.1  
no 50.1±31.5 39.6-60.6 0.609 
Ku80 expression    
Low(n=15) 42.3±26.9 27.4-57.2  
High(n=34) 55.3±30.2 44.8-65.8 0.159 
MGMT expression    
Low(n=23) 23.6±15.3 16.9-30.1  
High(n=26) 75.9±11.6 71.2-80.5  
Abbreviations : M, male; F, female; SL, single lobe; CA, central area; ML, Multiple lobes; CT, chemotherapy; 
RT, radiotherapy; RC, radiochemotherapy; CI, Confidence Interval; SD, Std. Deviation. 
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Baseline patient characteristics and Ku80 expression 
Study, n (%) Ku80（low） Ku80（high） p value 
Sex    
Male 7（14.3%） 19（38.8%）  
Female 8（16.3%） 15（30.6%） 0.551 
Age     
< 65 years 12（24.5%） 11（22.4%）  
≥ 65 years 3（6.1%） 23（46.9%） 0.006 
Tumor location    
Single lobe 6（12.2%） 11（22.4%）  
Multiple lobes 1（2.0%） 12（24.5%）  
Central area 5（10.2%） 6（12.2%）  
others 3（6.1%） 5（10.2%） 0.139 
Diagnosis    
Primary CNSL 15（27.3%） 34（61.8%）  
Secondary CNSL 2（3.6%） 4（7.3%） 1.000 
 
3.3 MGMT expression in PCNSL 
The level of MGMT expression was determined by MGMT 
immunohistochemistry. There is a considerable variability in MGMT expression level 
ranging between 5.4% and 94.4% in PCNSL (Mean 51.3%). The results of MGMT 
expression by age, gender, tumor location are presented in Tab. 5. 23 tumor samples 
(46.9%) demonstrated low MGMT staining (Positive rate < 50%, mean 23.6%±
15.3%), (Fig. 5, 6), and 26 (53.1%) tumor samples demonstrated intermediate and 
high MGMT expression respectively (positive rate >= 50%, mean 75.9%±11.6%), 
(Fig. 7, 8). The MGMT expression level in PCNSL (N = 49) was neither correlated 
with age of the patient nor with gender. There was no significant difference in MGMT 
expression between different locations of tumors (P=0.856). Differences in MGMT 
expression between primary and secondary CNS lymphomas did not reach 
significance (P=0.844). 
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Baseline patient characteristics and MGMT expression 
Study, n (%) MGMT（weak） MGMT（strong） p value 
Sex    
Male 13（26.5%） 13（26.5%）  
Female 10（20.4%） 13（26.5%） 0.648 
Age     
< 65 years 12（24.5%） 11（22.4%）  
≥ 65 years 11（22.4%） 15（30.6%） 0.490 
Tumor location    
Single lobe 9（18.4%） 8（16.3%）  
Multiple lobes 6（12.2%） 7（14.3%）  
Central area 4（8.2%） 7（14.3%）  
others 4（8.2%） 4（8.2%） 0.856 
Diagnosis    
Primary CNSL 23（41.8%） 26（47.3%）  
Secondary CNSL 2（3.6%） 4（7.3%） 0.844 
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  Fig. 1 Ku80 staining ×200                      Fig . 2 Ku80 staining ×400               
 
 
Fig. 3 Ku80 staining ×200                      Fig. 4 Ku80 staining ×400   
 
Fig. 1~4   Representative photomicrographs showing immunostaining for Ku80 in 
PCNSL samples. Fig. 1, 2 Immunohistochemical staining demonstrates the low 
expression of Ku80 in the PCNSL tissue, and strong nuclear staining could be 
observed in Fig. 3, 4.  
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  Fig. 5 MGMT staining ×200                      Fig. 6 MGMT staining ×400               
 
Fig. 7 MGMT staining ×200                     Fig. 8 MGMT staining ×400   
 
Fig. 5~8   Representative photomicrographs showing immunostaining for MGMT in 
PCNSL samples. Fig 5, 6 Immunohistochemical staining demonstrates the media 
expression of MGMT in the PCNSL tissue, and Fig 7, 8 demonstrates strong 
cytoplasmic staining. 
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3.4 Relevance analysis between Ku80 expression and MGMT expression 
Strong positivity of MGMT staining was observed in 23 (46.9%) of 49 
PCNSL cases and strong Ku80 expression was found in 15 (30.4%) patients. Among 
the 49 cases that were interpretable for both proteins, 21 cases (42.9%) were positive 
for both Ku80 and MGMT, 5 cases (10.2%) were positive only for MGMT, 13 cases 
(26.5%) were positive only for Ku80, and 10 cases (20.4%) were negative for both 
proteins (Tab 6). A strong trend was found toward poor prognosis in MGMT/Ku80 
positive as compared with MGMT/Ku80 negative cases. The difference, however, did 
not reach statistical significance by Kaplan-Meier analysis (P = 0.244), (Tab. 7.). No 
significant difference was observed between levels in Ku80 expression and MGMT 
expression (P=0.066). However, a correlation was found between the expression of 
these two proteins  (r=0.311, P=0.029). Co- expression of Ku80 and MGMT existed 
in patients with PCNSL. 
Correlation between Ku80 expression and MGMT expression 
 
3.5 Survival analysis in PCNSL 
 The Kaplan-Meier method was employed to calculate the progression-free 
survival and overall survival rates. The significance of the difference in the survival 
curves was calculated with the log-rank tests. Kaplan-Meier survival curves of 
patients were analyzed according to tumor location, surgical approach, treatment 
protocol, alkylating agents, and the expression of MGMT and Ku80. Tumor locations 
were divided into four groups stated as above: central area (such brain stem, thalamus, 
hypothalamus, and para- or intra-ventricular), a single cerebral lobe (such as frontal, 
temporal, parietal, occipital lobe), multiple cerebral lobes and other location (such as 
Location Protein Ku80(low) Ku80(high) Total 
MGMT(low)   10(20.4%)  13(26.5%)  23 
MGMT (high) 5(10.2%) 21(42.9%) 26 
Total 15 34 49 
31 
 
eye sockets or spinal). The treatment protocol was categorized into four groups 
described as above: chemotherapy, radiotherapy, radiochemotherapy and no chemo- 
or/and radiotherapy. These patients were also classified into alkylating agents group 
and non- alkylating agents group. The surgical approach was categorized into 
(stereotactic) biopsy and craniotomy. The expression of MGMT and Ku80 was 
evaluated by immunohistochemical staining, Those patients were divided into a weak 
expression group (Positive rate < 50%) and high expression group (Positive rate >= 
50%), there are comparable between these subgroups without statistical differences on 
the expression level of Ku80 and MGMT (Tab 3, P>0.05).  
Kaplan-Meier analysis revealed that patients who had high Ku80 expression 
had significantly shorter median survival time (MST) than patients who had low Ku80 
expression (55.3 months vs. 80.4 months; P =0.036; log-rank test) (Fig. 9). Different 
results were obtained for patients who had high and low MGMT expression 
(MST:59.7 months vs.63.9 months); but this difference did not reach statistical 
significance (p 0.706, long-rank test). Similarly, no difference was seenbetween 
patients who had undergone biopsy vs. patients who had undergone craniotomy (p 
0.796, log-rank test), Tumor location in central brain areas, as expected, was 
correlated with a significantly higher risk of death (P =0.014) (Fig. 10). Similar results 
were obtained for patients without any therapy compared to patients who underwent 
chemotherapy or/and radiotherapy (P =0.002) (Fig.11).Radiotherapy alone was not a 
significant prognostic factor for survival. Patients older than 65 years, as expected, 
were found to have a significantly higher risk of death (45.3 months vs. 78.6 months; 
P =0.011; log-rank test).  
       Kaplan-Meier analysis also discovered, that patients who underwent 
chemotherapy with alkylating agents had significantly longer MST than patients who 
didn’t (78.1 months vs. 41.2 months; P =0.007; log-rank test) (Fig.12). In addition to 
these, patients who underwent both alkylating agents and radiotherapy had 
significantly longer MST than patients who didn’t. However, it did not reach 
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statistical significance (67.5 months vs. 57.8 months; P =0.059; log-rank test). These 
findings supported the conclusion that alkylating agents play an important role in 
treatment of patients with PCNSL. In Tab.7, it is shown that patients’ age, tumor 
location, treatment protocol, alkylating agents and Ku80 were related with prognosis 
(OS) in PCNSL. Kaplan-Meier analysis between variables with PFS revealed the 
same statistical results as OS (Tab.8). 
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Tab. 7 Kaplan–Meier analyses for the correlation between variables and overall survival 
Variables OS Mean 95% CI log-rank test p value 
Sex     
Male 78.8 50.2-107.5   
Female 44.0 17.8-70.3 -2.677 0.102 
Age      
< 65 years 78.7 55.5-101.8   
≥ 65 years 45.3 17.1-73.6 6.486 0.011 
Tumor location     
Single lobe 40.1 20.3-59.9   
Multiple lobes 22.4 3.8-40.9   
Central area 71.9 46.7-97.2   
Others 123.9 86.2-161.6 10.664 0.014 
Surgical approach     
Biopsy 44.4 28.1-60.7   
Craniotomy 72.0 41.1-102.9 0.067 0.796 
Treatment protocol     
Chemotherapy 62.1 36.3-93.3   
Radiotherapy 62.1 57.1-121.3   
Radiochemotherapy 89.2 18.0-106.3   
No treatment 4.9 .00-10.3 14.727 0.002 
Chemotherapy     
Yes 83.2 59.8-106.7   
No 26.0 0.00-54.6 5.245 0.022 
Alkylating agents     
Yes 78.2 56.8-99.6   
No 41.1 12.3-69.8 7.295 0.007 
Radiotherapy     
Yes 73.5 41.9-105.1   
No 48.5 24.9-72.2 2.283 0.131 
Both alkylating agents and radiotherapy   
yes 67.5 46.8-88.2   
no 57.8 34.2-81.3 3.782 0.052 
Ku80 expression     
Low 80.4 53.5-107.2   
High 55.3 29.6-88.7 4.377 0.036 
MGMT expression     
Low 63.9 34.6-93.2   
High 59.7 34.3-85.1 0.142 0.706 
Co-expression     
Ku80/MGMT(+) 66.4 37.2-95.7   
Ku80(+) or MGMT(+) 75.4 43.4-107.5   
Ku80/MGMT(-) 39.5 14.1-64.8 2.824 0.244 
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Tab. 8 Kaplan–Meier analyses for the correlation between variables and PFS. 
Variables PFS Mean 95% CI log-rank test p value 
Sex     
Male 77.7 48.2-107.1   
Female 46.8 20.0-73.5 2.028 0.154 
Age      
< 65 years 78.2 54.69-101.7   
≥ 65 years 45.4 16.2-74.4 5.902 0.015 
Tumor location     
Single lobe 40.9 21.2-60.6   
Multiple lobes 20.9 1.6-40.3   
Central area 70.1 44.5-95.8   
Others 125.5 85.0-161.9 10.443 0.015 
Surgical approach     
Biopsy 45.6 29.4-61.7   
Craniotomy 70.7 39.1-102.2 0.061 0.806 
Treatment protocol     
Chemotherapy 64.7 35.9-93.4   
Radiotherapy 65.1 29.3-100.9   
Radiochemotherapy 89.9 58.0-121.9   
No treatment 3.0 0.0-8.1 13.294 0.004 
Chemotherapy     
Yes 83.7 60.2-107.2   
No 25.0 0.0-54.3 4.606 0.032 
Alkylating agents     
Yes 78.5 57.1-99.9   
No 40.3 10.9-69.6 6.845 0.009 
Radiotherapy     
Yes 74.7 42.1-107.3   
No 47.8 23.7-71.9 2.039 0.153 
Both alkylating agents and radiotherapy   
yes 67.2 46.1-88.3   
no 57.0 33.1-80.9 3.559 0.059 
Ku80 expression     
Low 79.2 51.7-106.7   
High 58.6 32.8-84.4 3.987 0.046 
MGMT expression     
Low 62.1 31.7-92.5   
High 61.2 36.2-86.3 0.002 0.964 
Co-expression     
Ku80/MGMT(+) 64.5 36.7-92.3   
Ku80(+) or MGMT(+) 74.2 41.5-106.9   
Ku80/MGMT(-) 43.3 19.1-67.5 1.709 0.426 
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Fig. 9                                      Fig. 10                 
 
 
         Fig. 11                                           Fig. 12     
 
 Fig. 9~12 Kaplan-Meier survival curves of patients with PCNSL and its impact on 
overall survival were analyzed according to the expression level of Ku80 (Fig. 9,tumor 
location (Fig. 10), treatment protocol (Fig. 11), the use of alkylating agents (Fig. 12)  
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4. DISCUSSION 
PCNSL has been paid more attention in recent years. Especially its 
unsatisfactory therapy and poor prognosis has been noticed, resulting in an increasing 
scientific awareness [3, 5, 7]. It is clear that its unsatisfactory therapy and poor 
prognosis are connected with the chemosensitivity and radiosensitivity [2, 26]. 
Special attention has been paid in recent years to factors related to the molecular 
biological characteristics of the tumor, in an attempt to predict and improve the 
prognosis. This study was aimed at detecting the expression of MGMT and Ku80 on 
PCNSL by IHC staining to evaluate the relationship between Ku80, MGMT 
expression levels and the clinical outcome, thus determine whether these 
immunophenotypes were prognostic markers in PCNSL. A second goal was to find 
out more about the general characteristics and prognosis of PCSNL. 
4.1 Ku80 expression level in PCNSL and outcome, Ku80 may be a prognostic 
marker.  
Despite many studies performed with established cell lines, little is known 
about Ku80 expression in lymphoma. The expression Ku80 in primary central 
nervous system lymphoma or DLBCL has not been published. The Ku70 showed 
relatively equal expression in different normal tissues, but Ku80 expression was 
somewhat more variable from tissue to tissue [63]. This study is the first to detect the 
expression Ku80 in primary central nervous system lymphoma tissue. The results of 
our exploratory study showed that a wide range expression of Ku80 was found among 
samples obtained from PCNSL patients. A considerable Ku80 expression level in 
PCNSL was found with mean expression rate 64.1%. A high expression of Ku80 
correlated with a poor prognosis of PCNSL. The results of Ku80 expression by gender, 
tumor location showed no significant difference. 
These result suggest significant difference between Ku80 expression (weak 
or high) and patients’ age in our study, when patients were divided into two groups 
with separation younger/older than 65 years. Different statistical methods lead to 
different results, one of reasons is that this graded statistical method has its shortage 
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of loss of some information. Enlarging sample sizes and more layers graded could 
make up for its defect and reduce the loss of information. One also may explain that 
the difference of Ku80 expression between different age groups may be due to  
age-dependent changes in tumor. It is also reported that among the DSB repair 
proteins tested, the expression of Ku70 showed statistically significant age- dependent 
changes in human lymphocytes, but the expression of Ku80 didn’t [64] . Whether 
Ku80 expression is age-dependent in PCNSL is still unknown. 
The success of DSB repair in tumor cells with high expression of Ku80 is the 
major cause for radiotherapy failure, leading to prolonged tumor cell survival, and 
tumors with a low percentage of Ku80-positive cells tend to be radiosensitive. Ku80 
may be a potential prognostic marker for the prediction of radiotherapy outcome. In 
our study, Kaplan-Meier analysis revealed that patients who had high Ku80 
expression had significantly shorter MST than patients who had a low Ku80 
expression (P =0.036). This observation suggested that Ku80 expression might be of 
prognostic significance in the patients with PCNSL whose tumor cells manifest higher 
levels of Ku80 expression. However, the influence of Ku80 on survival in patients 
with and without radiotherapy, no statistical significance was found (P>0.05). So, 
Ku80 may be a marker to prognosis, but can’t predict the therapeutic effectiveness of 
radiotherapy, and of course can’t work as an indicator to radiotherapy. 
Although it is supported that Ku protein expression is correlated with 
radiation treatment outcome [53-55] [56], there are exceptions, some stated that Ku80 
expression is no correlated with radiation sensitivity [65]. Although Ku80 levels were 
detected to correlate significantly to OS in our study, there was no significance found 
between radiotherapy and outcome. This observation supports Kasten-Pisula results 
that Ku80 expression is not correlated with radiation sensitivity. It may be one 
explanation that Ku80 play a role on the repair of DNA ends by nonhomologous end 
joining (NHEJ) cooperated with other compounds such as Ku70, DNA-PKCS, Xrcc4, 
DNA ligase IV and others.  
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A slight increase in cellular levels of Ku80 after irradiation in both human 
fibroblasts and lymphoblasts could be shown, while the expression of Ku70 
remarkably increased [51]. This observation suggests that a radiation-resistant 
phenotype is determined by Ku70 expression. On the other hand, a remarkable 
increase of Ku80 expression, compared to Ku70 expression, occurred after irradiation 
[56]. The expression and functions Ku80 maybe vary widely in various tumors. 
Although the exact functions of Ku70 and Ku80 are not yet known, the induction of 
Ku80 expression by ionizing radiation is a key step in radiation resistance. 
4.2 MGMT expression level in PCNSL 
Most association analyses between MGMT and lymphoma were performed 
in DLBCL subgroup of systemic lymphoma. The MGMT status in other subgroup 
lymphoma is still unclear. The expression of MGMT protein tested by IHC is rarely 
reported. MGMT protein protects cells from toxicity of alkylating agents that 
frequently target the O6 position of guanine [66]. It is therefore assumed that the good 
prognosis of DLBCL with low MGMT expression was caused by a better response to 
alkylating agents such as cyclophosphamides. Esteller et al reported that MGMT 
promoter hypermethylation appears to be a useful marker for predicting survival in 
patients with DLBCL treated with multidrug regimens [67]. A significant difference of 
the prognosis was observed between DLBCL with and without silencing of the DNA 
repair enzyme MGMT in DLBCL [68]. Similar results were described by Al-Kuraya 
et al [66]. Recently, Lee and his co-workers concluded that aberrant promoter 
methylation of MGMT is an additional biological marker for an increased overall 
survival in patients with DLBCL[69]. 
However, the MGMT status in PCNSL and its correlation to clinical outcome 
is still unknown. MGMT methylation in one of three patients with PCNSL was 
reported by Gonzalez-Gomez [39]. Chu et al found promoter methylation of MGMT 
in PCNSL was correlated with the loss of MGMT protein expression. There is also 
evidence that MGMT methylation status may be an important predictor for the 
response to alkylating agents in patients with PCNSL [70].  
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In our study, the level of MGMT expression was detected by IHC method in 
49 patients with PCNSL. 26 (53.1%) tumor samples demonstrated intermediate and 
high MGMT expression respectively. Consistent with our results, Chu, et al observed 
a similar rate of MGMT expression in PCNSL with methylation-specific PCR method 
[70]. There are no significant differences in MGMT expression level with patients’ 
gender, age, and locations of tumors. No significant difference on survival between 
patients who had high MGMT expression and patients with low MGMT expression 
was observed by Kaplan-Meier method (P =0.706, log-rank test). So, in the present 
study, MGMT protein expression can not be considered a predictor to 
chemotherapeutic response and prognosis in patients with PCNSL.  
We showed in our study that patients treated with alkylating agents had a 
significantly longer MST (P =0.007). This supports the conclusion that alkylating 
agents play an important role in chemotherapy outcomes in patients with PCNSL. 
There are three possible explanations to ths surprising result: a) This phenomenon is 
caused by an error of analysis techniques, it may be one way to choose adequate 
method or combine with other methods such as methylation specific PCR for 
preferable assessing the MGMT status. b) Sample size is not enough, further analysis 
with larger number of cases is necessary to clarify the utility of MGMT 
immunohistochemistry as a predictor of prognosis of PCNSL. c) Given alkylating 
agents prescribed as part of multidrug regimens, alkylating agents play a role on 
tumor cells through other mechanisms [71], for example, its synergy with other 
chemotherapy drugs, bi-functional alkylating activity [72], or its bimodal mechanism 
of antitumor action with cytotoxic and immunomodulatory effects [73]. Marchesi et al. 
reviewed that the biological effects of triazene compounds depends on at least three 
DNA repair systems: a) O6-alkylguanine-DNA-alkyltransferase, called also 
methyl-guanine methyl-transferase (MGMT) b) mismatch repair (MMR), and c) base 
excision repair (BER) [71]. 
We conclude that alkylating agents play an important role in treatment of 
patients with PCNSL, but the expression level of MGMT is not a predictor of a 
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successful alkylating treatment. To proof this hypothesis further studies and larger 
case series might be necessary. 
4.3 Ku80 and MGMT level in primary CNSL and secondary CNSL 
More and more clinical trials and studies are no longer only based on the 
histological diagnoses, but also take into consideration the molecular markers such as 
the MGMT promoter methylation. It is well known that biomarkers expressed in CNS 
DLBCL are not of the same prognostic significance as in non- CNS DLBCL. 
Although, the vast majority of primary CNSL and secondary CNSL are DLBCL 
according to histological classification [2]. The role of Ku80, MGMT and the 
relevance for the different clinical characteristics of primary and secondary CSNL is 
unclear. There is no recent literature regarding this issue. 
Our attention was therefore directed on detecting the expression of Ku80 and 
MGMT in primary CNSL and secondary CNSL. To keep it short, we could not find 
significant difference for both Ku80 and MGMT in primary CNSL compared with 
secondary CNSL. We can only speculated, that the expression of Ku80 and MGMT in 
CNSL may be determined by his DLBCL histological subtype.  
4.4 Ku80 and MGMT co-expression in PCNSL 
High Ku80 expression was associated with reduced survival in Kaplan-Meier 
analysis. There was no significant impact of MGMT expression on prognosis. A 
strong trend was found toward poor prognosis in MGMT/Ku80 positive as compared 
with MGMT/Ku80 negative cases. The difference, however, did not reach statistical 
significance (P = 0.244). Furthermore, we found that expressions of Ku80 and MGMT 
are statistically correlated (p=0.029), which indicate that the expression of Ku80 and 
MGMT may be related. 
Both Ku80 and MGMT are DNA repair genes; they play an important role on 
protecting tumor cells against DNA injuries caused by chemotherapy and radiotherapy. 
The Ku80, as one of the subunit of Ku complex, plays a key role in multiple nuclear 
processes, for example, the repair of DNA ends by nonhomologous end joining 
(NHEJ), chromosome maintenance, transcription regulation and VJ recombination 
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[43-45], whereas the MGMT-mediated repair process is unique and differs from other 
DNA repair pathways as MGMT is not part of a repair complex but acts alone [27]. 
There may be some unknown molecular biological mechanism making the regulation 
of their co- expression in human tumor cells.  
4.5 Prognostic factors in PCNSL 
The biological mechanism involved in pathogenesis of PCNSL is complex 
but deserve further study. It is possible and important to search appropriate prognostic 
factors not only for division of patients with PCNSL into specific risk groups for 
identification and assessment of appropriate therapies, but also for predicting the 
survival. The traditional markers of prognosis in non-Hodgkin's lymphoma, which 
form the International Lymphoma Study Group classification[74]—namely, 
performance status, LDH levels, and disease stage—may be not of prognostic markers 
in PCNSL.  
Age and performance status (PS) are the only two universally accepted 
prognostic factors [23, 75, 76]; several other potential prognostic parameters such as 
histotype, duration of symptoms, subtentorial localization, and bilateral brain 
involvement were proposed but failed to be confirmed in subsequent studies. Recently, 
the IELSG prognostic score, which consisted of 5 parameters: age, KPS, serum LDH 
level, CSF protein concentration and involvement of deep regions of the brain, are 
correlated with a negative prognosis in PCNSL [22].  
In our survival analysis, the expression of Ku80 was considered as an 
important predictor, whereas MGMT was no statistically significant, although it was 
discovered that MGMT is an independent prognostic marker in DLBCL [66]. 
Therefore usefulness of MGMT immunohistochemstry for the prediction of 
chemosensitivity of PCNSL is limited. It is not surprising that age is a prognostic 
factor as expected in this study. In addition to Ku80 and age, this study reported an 
independent prognostic role of the involvement of location of the tumor in PCNSL 
patients. In fact, the involvement of periventricular regions, basal ganglia, brainstem, 
and/or cerebellum was associated with a poor prognosis. Treatment protocol and 
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alkylating agents played a prognostic role independent of age and PS with statistically 
significance. Nevertheless, it is plausible that age and PS have influenced patient’s 
selection to receive more or less aggressive therapy such as chemotherapy 
combinations and doses. It is concluded that patients’ age, tumor location, treatment 
protocol and the use alkylating agents are factors to predict prognosis in patients with 
PCNSL.  
4.6 MGMT analysis techniques 
It is noteworthy that most MGMT analyses in the literature were performed 
retrospectively using a variety of different techniques. Large intergroup prospective 
studies utilizing standardized techniques are therefore necessary to validate such 
findings. A number of methods have been described to assess the status of the MGMT: 
a MSP assay for methylation status of the MGMT gene promoter region, 
reverse-transcription (RT)–PCR for MGMT mRNA expression, IHC and a 
quantitative protein expression assay using western blotting and many others. The 
best technique for evaluating MGMT status is still a matter of debate.  
More recently, the use of polymerase chain reaction (PCR) allowed the 
analysis of small populations of cells from tissue fragments or cerebrospinal fluid. 
There is growing acceptance that MGMT promoter methylation assessment by 
methylation specific PCR (MSP) is more accurate than detection by 
immunohistochemistry (IHC) because MGMT promoter methylation does not 
correlate well with MGMT protein expression [77]. Most authors recommend 
assessment of MGMT promoter methylation status using the more specific MSP 
technique which requires frozen tumor sections for optimal results.  
However, MSP is a relatively complicated and time-consuming method, not 
available generally in the local hospital. In addition, the formalin fixation and paraffin 
embedding of tumor tissues deteriorates the DNA quality in the tissue, which may 
lead to failure of amplification by MSP, particularly in small samples (e.g., 
stereotactic biopsies) [78]. Requiring fresh vital tissues or fresh frozen specimens 
limits the applicability of this method in routine practice.  
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Some authors prefer to IHC technique for evaluating MGMT status because 
promoter methylation status does not always reflect protein expression. There are 
several potential advantages of IHC compared with MSP. IHC, as a routinely reliable 
method in diagnostic histopathology, is commonly available in most laboratories. 
Furthermore, IHC is less expensive than MSP and works on formalin-fixed and 
paraffin-embedded tissues. Several studies have reported there is a significant 
correlation between immunohistochemically assessed MGMT expression and patient 
outcome in glioma [78-81]. Some more recent studies reported that pre- therapy 
analysis of MGMT protein expression in malignant gliomas may help to identify 
patients in whom tumors are resistant to TMZ. Anda et al reported strong 
immunohistochemical MGMT staining in 18 patients with glioblastomas may show 
more chemoresistance to alkylating drugs [79]. Chinot et al found patients that 
MGMT expression is correlated with response to TMZ in 29 glioblastoma [80]. 
Similar results were reported for pediatric patients with malignant gliomas [81]. So 
there is great interest in the clinical use of MGMT immune- staining. According to 
their respective advantages and shortcomings, it is essential to choose the adequate 
method or combine these techniques for preferable assessing the MGMT status. For 
these reasons, we preferred IHC to evaluate the expression of MGMT in our study. 
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5. CONCLUSIONS  
The expression of Ku80 and MGMT was observed in the majority of 
PCNSLs, and without statistical difference compared with their expressions in 
secondary CNS lymphoma. It is the first time to detect the expression of Ku80 
proteins in PCNSL with IHC method. Ku80 was predictive for survival in this study. 
Immunohistochemical detection of MGMT in PCNSL does not correlate with overall 
survival, and cannot be used as a prognostic factor. In addition to Ku80 expression, 
other clinical variables including tumor location, treatment protocol and alkylating 
agents are correlated significantly with overall survival. The role of these variables 
and the clinical relevance deserve to be assessed in further studies.  
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7. SUMMARY 
The primary central nervous system lymphoma (PCSNL), as one of the 
uncommon extranodal lymphomas, has been recently paid more attention especially 
for its increasing incidence, unsatisfactory therapy and poor prognosis. MGMT is one 
of the most important factors determining drug resistance while Ku80 determining 
radiosensitivity, the expression of MGMT and Ku80 in PCNSL remains unclear. The 
aim of our study was to detect the expression of MGMT and Ku80 on PCNSL by IHC 
staining and to evaluate the relationship between Ku80, MGMT expression level and 
clinical outcomes, thus determine whether these immunophenotypes were prognostic 
factors in PCNSL.  
49 patients with PCNSL were included in this retrospective study. The 
expression of Ku80 and MGMT in tumor samples was determined by 
immunohistochemistry using the Ku80 and MGMT monoclonal mouse antihuman 
antibody. One thousand neoplastic cells per specimen were counted. On the basis of 
the percentages of positive cells in the tumors, these tumors were defined as low 
Ku80 expression or low MGMT expression when there are no or fewer than 50% 
positive cells, and high expression when positive rate was more than 50%. The 
expression levels were than compared to the clinical data and statistical analyzed. 
The mean expression level of Ku80 and MGMT in 49 PCNSL were 
64.1±24.5 and 51.3±29.5 respectively. A correlation was found between these two 
proteins expressions (r=0.311, P=0.029). A significant difference in Ku80 expression 
could be found between age<65 years group and age≥65 years group (P=0.006), 
Differences in Ku80 and MGMT expression between primary and secondary CNS 
lymphomas did not reach significance (P>0.05). Kaplan-Meier analysis revealed that 
patients who showed a high Ku80 expression had a significantly shorter median 
survival time (MST) than patients who had low Ku80 expression (55.3 months vs. 
80.4 months; P =0.036). This could not be observed for the MGMT expression. 
Patients’ age, tumor location, treatment protocol, alkylating agents were significantly 
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related with prognosis in PCNSL (P<0.05).  
The results of this study show that the expression of Ku80 and MGMT can 
be found in the majority of PCNSLs, although without statistically difference 
compared with their expressions in secondary CNS lymphoma. It is the first time to 
detect the expression of Ku80 proteins in PCNSL. Ku80 expression was a positive 
predictor for survival in this study. Immunohistochemical detection of MGMT does 
not correlate with overall survival, and cannot be used as a prognostic factor. With 
Ku80 we can add another predictor to evaluate the prognosis in patients with PCSNL 
and confirm the relevance of patient age and tumor location at the time of diagnosis in 
the prognosis of PCSNL. 
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8. Abbreviation List 
ALL             Acute lymphocytic leukemia  
Ara-C            Cytarabine  
BER             Base excision repair 
CHOP            Cyclophosphamide, hydroxydaunorubicin (Adriamycin),    
Oncovin (vincristine), and prednisone/prednisolone 
CLL              Chronic lymphocytic leukemia 
CNS              Central nervous system 
CP               Cyclophosphamide 
CR               Complete remission  
CSF              Cerebrospinal fluid 
DLBCL           Diffuse large B-cell lymphoma 
DNA-PKcs        DNA-PK catalytic subunit 
DNA-PK          DNA-dependent protein kinase 
DSB              DNA double-strand breaks  
GBM             Glioblastoma multiforme 
HCL              Hydrogen chloride 
IELSG            The International Extranodal Lymphoma Study Group 
IFO               Ifosphamide 
IHC              Immunohistochemistry 
KPS              Karnofsky performance status 
LDH              Lactate dehydrogenase 
MGMT            O6-MethylguanineDNAmethyltransferase 
MMR             Mismatch repair 
MSP              Methylation specific PCR 
MST              Median survival time  
MTX              Methotrexate 
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NaCl              Sodium Chloride 
NHEJ             Nonhomologous end joining 
NOVEP           Mitoxantrone, Etoposide and Prednisolone 
OS               Overall survival 
PBS              Phosphate buffered saline 
PCNSL             Primary central nervous system lymphoma 
PFS              Progression-free survival 
PR               Partial remission 
PS               Performance status 
REAL            Revised European-American Lymphoma 
RT–PCR          Reverse-transcription polymerase chain reaction 
TBS             Tris-buffered saline 
TMZ                Temozolomide 
WBRT           Whole-brain radiotherapy 
WHO            World Health Organization 
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